AMENDED AND RESTATED EXECUTIVE COMPENSATION AGREEMENTExecutive Compensation Agreement • July 28th, 2022 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • Nevada
This Amended and Restated Executive Compensation Agreement (“Agreement”) is entered into as of May 8, 2022, effective as of January 1, 2022 (“Amendment Date”), by and between PharmaCyte Biotech, Inc. a Nevada corporation (together with its successors and assigns, “Company”), and Carlos A. Trujillo (“Trujillo”). The Company and Trujillo are each referred to in this Agreement as a “Party” and collectively as “Parties.”
AMENDED AND RESTATED EXECUTIVE COMPENSATION AGREEMENTExecutive Compensation Agreement • July 28th, 2022 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • Nevada
This Amended and Restated Executive Compensation Agreement (“Agreement”) is entered into as of May 8, 2022, effective as of January 1, 2022 (“Amendment Date”), by and between PharmaCyte Biotech, Inc. a Nevada corporation (together with its successors and assigns, “Company”), and Kenneth L. Waggoner (“Executive”). The Company and the Executive are each referred to in this Agreement as a “Party” and collectively as “Parties.”
